Selank Peptide: What the Research Actually Says

Selank is a synthetic seven-amino-acid peptide — Thr-Lys-Pro-Arg-Pro-Gly-Pro — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and studied as an anxiolytic in Russian clinical research. It is a modified version of tuftsin, a short peptide the body makes itself from immunoglobulin G: the tuftsin core with three extra residues attached, which stop enzymes from breaking it down so quickly. In Russia it is a registered medicine sold as nasal drops. In the United States it is not an FDA-approved drug and not an approved compounding ingredient.

That last sentence is the part most pages on this subject skip, and it matters more than any benefit list. Below is what Selank is, what its registered label in Russia actually says, what the human studies did and did not find, how it differs from Semax, and where it stands with the FDA — sourced, with the weak points named rather than smoothed over.

What Selank actually is

Tuftsin is a four-amino-acid fragment (Thr-Lys-Pro-Arg) released from the heavy chain of immunoglobulin G, with known immune-signalling activity. On its own it is destroyed in the bloodstream almost immediately. Selank is that fragment with Pro-Gly-Pro added to the end, a modification that makes it far more resistant to peptidases while keeping the parent molecule’s activity.

Its molecular formula is C₃₃H₅₇N₁₁O₉, molar mass about 752 g/mol, PubChem CID 11765600. In research papers and on FDA documents it also appears as TP-7. It is a genuine peptide — unlike some compounds marketed alongside it, which are small molecules wearing the word as a label.

What Selank is registered for, and where

This is the single clearest fact about Selank and almost nobody states it accurately. Selank is a registered medicine in Russia, marketed as Селанк (Selank) 0.15 percent nasal drops, 1.5 mg of peptide per millilitre, by AO Peptogen in Moscow. It is classified under ATC code N05BX, “other anxiolytics,” and is sold over the counter there.

The registered indications on that label are, for adults over 18 only: anxiety states including unmotivated worry and panic attacks; neurasthenia and asthenia; mood instability; sleep disturbance; reduced initiative and difficulty making decisions; low confidence in communication; adjustment disorders; and prevention and treatment of stress disorders.

Two things follow from this that are worth being precise about. First, several Western pages say Selank is “approved in Russia for generalized anxiety disorder.” That is a paraphrase of the trial population, not the label — the label says “anxiety states” and neurasthenia, which is a broader and looser category. Second, and more importantly for anyone reading this in California: a Russian marketing authorisation has no standing in the United States. It tells you a regulator somewhere reviewed a dossier. It does not tell you the FDA has.

How Selank is thought to work

Three mechanisms appear consistently in the literature, and they differ considerably in how well established they are.

GABAergic modulation — stated more confidently elsewhere than the data support. Volkova and colleagues, writing in Frontiers in Pharmacology in 2016, measured 84 neuroreception genes in rat frontal cortex one and three hours after Selank or GABA at 300 µg/kg. Forty-five genes changed significantly at one hour, and the changes correlated with those produced by GABA itself. The authors concluded that one possible mechanism involves allosteric modulation of the GABAergic system. That is a reasonable inference from gene expression — but it is not receptor-binding data, and a 2017 follow-up by Filatova and colleagues found no direct effect on GABAergic gene expression in a neuroblastoma cell line. Pages that tell you Selank “is a positive allosteric modulator of GABA-A receptors and enhances GABA binding affinity” are stating as fact something the evidence suggests but has not demonstrated.

Enkephalin preservation — the one mechanism with human data behind it. Kost and colleagues showed in 2001 that both Semax and Selank inhibit the enzymes that degrade enkephalins, the body’s own opioid-like signalling peptides. In the clinical study described below, patients had a shortened half-life of serum leu-enkephalin at baseline, and that measure rose during Selank treatment. It is a small biomarker finding, but it is a human one.

BDNF and immune signalling. Intranasal Selank altered BDNF expression in rat hippocampus (Inozemtseva and colleagues, Doklady Biological Sciences, 2008), and a human study reported effects on interleukin-6 and the Th1/Th2 cytokine balance — unsurprising for a tuftsin derivative, since tuftsin is an immune peptide to begin with.

In plain terms: Selank appears to nudge several signalling systems at once rather than binding one receptor hard, which is the usual pattern for regulatory peptides. It is also why its effects are described as subtle rather than sedating.

What the human studies actually found

Here is the honest summary, and it is the part worth reading twice: there is no placebo-controlled trial of Selank, no trial conducted outside Russia, and no independent replication. The human literature is roughly four peer-reviewed papers, all in Russian, all in the same journal, all involving the institute that developed the compound, totalling somewhere around 200 patients.

Read that table the way a clinician would. Every comparison is against an active drug, never placebo — which means none of these studies can separate the compound’s effect from expectation. The largest is seventy people. The full texts are in Russian; what exists in English is abstracts, without effect sizes or p-values. That is not the same as evidence of no effect, and the consistency across studies is mildly encouraging. It is simply a long way from what would be needed for a US approval, and anyone presenting it as settled is overselling.

Selank versus Semax

These two are constantly sold together, including as a 50:50 blend, because they came out of the same Russian research programme and are often described as complementary. They are genuinely different molecules with different parent compounds.

The rationale usually given for the combination is that the two pull in opposite directions — one steadying, one activating — and that together they avoid either extreme. It is a plausible idea. It is also worth saying clearly that no study has tested Selank against Semax head to head, and no study has tested the blend. The 50:50 ratio is a formulation convention, not a trial result. Our Semax guide covers that compound in detail, and the Semax/Selank 50:50 combination and Semax on its own are both on our menu.

Nasal spray or injection?

Selank’s registered form in Russia is nasal drops, and the intranasal route is the one the pharmacology was built around. The label reports absolute bioavailability across the nasal mucosa of 92.8 percent, with the peptide detectable in plasma within thirty seconds and plasma concentration falling away over roughly five to five and a half minutes. Nothing — parent compound or metabolite — is recoverable in twenty-four-hour urine, because tissue peptidases dismantle it completely.

That very short plasma presence is worth sitting with, because it tells you something useful: whatever Selank does, it is not doing it by maintaining a blood level. The reported effects outlast measurable drug by a wide margin, which points to downstream signalling rather than ongoing occupancy. It also means the common vendor claims about a specific half-life in minutes or hours are not traceable to any published measurement, and we would rather say so than repeat one.

The preparations we carry are listed on our Selank page, in both nasal spray and injectable form, and neither is dispensed without a consultation first.

Injectable preparations exist and are used, but the comparative question — whether subcutaneous injection produces a different or better result than intranasal — has not been answered in a published human study. One mouse experiment found the two routes produced different receptor-binding patterns in the brain, which is intriguing and not a basis for choosing. Practically, the nasal route is what the evidence base used and what the registered product is.

What the Russian label specifies for dosing

There is no established dose of Selank in the United States, because there is no approved use. What exists is the dosing on the Russian registered label, which we quote as a regulatory fact rather than as a protocol to follow:

• Two drops into each nostril, three times daily, of the 0.15 percent solution
• A 14-day course, repeatable after one to three weeks on a physician’s advice
• Adults over 18 only

Note what the label does not do: it gives no microgram figure. Dosing is specified in drops, which means the milligram amount depends on the dropper. Figures circulating online of 250, 300, 1,800 or 2,700 micrograms per day are not from the label, and the one published human study we found that names a microgram dose is a conference abstract rather than a peer-reviewed paper. If you see a confident mcg-per-day protocol presented as “the clinical dose,” it is not coming from the regulatory record.

Side effects and who should not use it

The Russian label is the only regulatory safety document that exists for Selank anywhere, and it is notably sparse — which cuts both ways. What it lists, all at unknown frequency:

• Allergic reactions, including delayed ones. The formulation contains methylparahydroxybenzoate as a preservative, which carries its own allergy warning.
• An unpleasant taste as the solution drains from the nasal cavity to the throat — the most commonly described practical nuisance.

Contraindications on the label are hypersensitivity, pregnancy, breastfeeding, and age under 18 — and the stated reason for the last three is simply that no clinical studies were conducted in those groups. The label also records no established interaction with haloperidol, barbiturates, analeptics or alcohol. Read that list carefully: it is short and specific, and it does not include SSRIs, SNRIs, benzodiazepines or stimulants, for which no interaction data exist at all.

Beyond the label, the honest answer is that long-term safety data do not exist. Reports of nasal irritation, headache, dizziness, fatigue and transient overstimulation appear in clinical commentary rather than in trials. Claims that Selank causes hair thinning circulate online with no supporting evidence, and we are not going to repeat the mechanism sometimes offered for them. Equally, pages asserting that Selank has “no side effects” or “no dependency risk” are making a claim the data cannot carry.

Selank is not appropriate for you if you are pregnant or breastfeeding, under 18, have a known hypersensitivity to the peptide or to paraben preservatives, or are taking psychiatric medication — in that last case not because an interaction is documented, but precisely because none has been studied. It is also not a substitute for psychiatric care. If what you are dealing with is persistent, worsening or affecting your daily functioning, the right next step is an evaluation with a mental health clinician, not a peptide.

Where Selank stands with the FDA

This is where most pages are vague and a few are simply wrong, so here it is plainly.

• Selank has no FDA approval for any indication, and it is not a controlled substance.
• It is not on the FDA’s 503A bulk drug substances list. Selank acetate (TP-7) appears instead in the agency’s table of substances that were nominated but withdrawn — the nomination was pulled, so it never made it onto the permitted list.
• Withdrawal is not permission. A substance that is not on the 503A list, has no USP monograph and is not a component of an approved drug cannot lawfully be used as a compounding ingredient under section 503A. Any page describing Selank as available in a “compounding format” is glossing over this.
• The FDA’s stated concern is specific: compounded preparations containing selank acetate may pose a risk of immunogenicity for certain routes of administration, because of the potential for aggregation and peptide-related impurities, and the agency lacks important information about safety issues in humans.
• It is not named on the WADA 2026 Prohibited List. Whether it falls under the S0 catch-all for non-approved substances is genuinely unsettled, since S0 covers substances with no approval from any governmental health regulator and Selank does hold a Russian authorisation. A drug-tested athlete should check with their anti-doping organisation rather than assume either answer.

The practical consequence for a patient is the same one that applies to every compound in this category: what you are being offered is not an approved medicine, and the identity, purity, concentration and sterility of whatever is in the bottle depend entirely on who made it. That is a question to put to a provider, alongside baseline blood work, rather than a purchase to make from a website.

Frequently asked questions

Is Selank a nootropic?

It is usually filed under that heading, though the label it was registered under in Russia is “other anxiolytics,” not a cognitive drug. The Russian trials reported mild nootropic-type effects alongside the anxiolytic ones — better described as reduced mental fatigue than as enhanced cognition. If cognitive performance is the actual goal, Semax has the more cognition-focused research behind it, and our guide to peptides for brain fog covers the wider category.

How do you feel on Selank?

The consistent description, in both the Russian studies and clinical commentary, is a reduction in tension without sedation — the distinction people usually draw is that it does not feel like a benzodiazepine. Zozulya’s trial found the anxiolytic effect comparable to medazepam while also noting antiasthenic and mildly stimulating effects, which fits that account. Worth being clear, though: none of these studies had a placebo arm, so subjective reports cannot be separated from expectation.

Does Selank help sleep?

Sleep disturbance appears among the registered indications on the Russian label, in the context of anxiety and stress states rather than as a sleep medication in its own right. There is no trial measuring sleep architecture or sleep quality as a primary endpoint. If sleep is the main concern, that is a different conversation — our guide to sleep-focused peptide protocols is the more relevant starting point.

Does Selank nasal spray need to be refrigerated?

Peptide solutions are generally stored cold, and compounded preparations should be kept according to the instructions on the specific bottle you were given, since formulation and preservative content vary between preparations. Do not rely on a general rule from a forum for a product that someone else compounded — ask the provider who supplied it.

Is Selank addictive?

The Russian label states that it does not produce dependence or tolerance. That is a manufacturer’s label assertion rather than an independently replicated finding, and there is no long-term human study that would confirm or refute it. The more defensible statement is that no dependence has been reported in the small body of research that exists, which is not the same thing as it having been ruled out.

Can Selank be taken with antidepressants?

No interaction studies have been done with SSRIs, SNRIs, benzodiazepines or stimulants. The Russian label records only that no interaction was established with haloperidol, barbiturates, analeptics and alcohol. Absence of data is not reassurance, and this is exactly the situation where a decision belongs with the clinician who manages your prescriptions rather than with a product page.

Important medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Selank is not an FDA-approved drug and is not approved in the United States for any indication; selank acetate is not on the FDA’s 503A list of bulk drug substances permitted for compounding, and the FDA has stated that compounded preparations containing it may pose a risk of immunogenicity due to aggregation and peptide-related impurities. This article is educational. It is not medical advice, not a substitute for evaluation by a qualified clinician, and not a claim that Selank diagnoses, treats, prevents or cures anxiety, depression, ADHD, PTSD or any other condition. The clinical evidence for Selank consists of a small number of Russian-language studies with no placebo control and no independent replication. Selank is contraindicated in pregnancy, breastfeeding and under-18s, and no interaction data exist for psychiatric medications. Persistent or worsening psychological symptoms warrant assessment by a mental health professional. Do not obtain or self-administer research-grade peptides purchased online.

Sources referenced

Zozulya AA, Neznamov GG, Siuniakov TS, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008;108(4):38–48. · Medvedev VE, Tereshchenko ON, Israelyan AY, et al. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2014;114(10):22–29. · Medvedev VE, Koliutskaia EV, Andriushchenko AV. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015;115(8):34–39. · Uchakina ON, Uchakin PN, Myasoedov NF, et al. “Immunomodulatory effects of selank in patients with anxiety-asthenic disorders.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008;108(5):71–75. · Volkova A, Shadrina M, Kolomin T, et al. “Selank administration affects the expression of some genes involved in GABAergic neurotransmission.” Frontiers in Pharmacology, 2016;7:31. · Filatova E, et al. Frontiers in Pharmacology, 2017;8:89. · Inozemtseva LS, Karpenko EA, Dolotov OV, et al. “Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.” Doklady Biological Sciences, 2008;421:241–243. · Kost NV, Sokolov OI, Gabaeva MV, et al. “Semax and selank inhibit the enkephalin-degrading enzymes from human serum.” Bioorganicheskaia Khimiia, 2001;27(3):180–183. · Vyunova TV, Andreeva LA, Myasoedov NF. “The molecular aspects of heptapeptide selank biological activity.” Current Medicinal Chemistry, 2018;25(30):3577–3586. · Registered instruction for medical use, Selank 0.15% nasal drops, registration certificate ЛП-№(010951)-(РГ-RU), AO Peptogen, Russian Federation. · US Food and Drug Administration, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” — selank acetate (TP-7), nominated but withdrawn. · World Anti-Doping Agency, Prohibited List 2026. · National Center for Biotechnology Information, PubChem compound summary for Selank, CID 11765600.

Medically reviewed by Biana Borchenko, FNP-BC (A4M) — Robertson Wellness & Aesthetics, Beverly Hills.